Sir -We were surprised to read in your journal the conclusion of Plowman et al. (1986) that 'two postmenopausal women showed an objectively measured response and durable remission of metastatic breast cancer (in bone and lungs respectively) following therapy with the potent LHRH analogue ICI 118630'.
From the data presented by the authors we would point out the following -We accept that the eight non-responders were post-menopausal being either over 60 years of age or having had bilateral oophorectomy performed. However, of the two 'responders', patient 2 had her last period only 3 years previously and from her hormone levels had some ovarian function which would be blocked by Zoladex. Although patient 1 was post-menopausal we would point out that a bone scan is not accepted in the UICC criteria (Hayward et al., -1977) for the objective measurement of response in patients with metastatic breast cancer. Finally it was reported that the bone scan showed 'improvement' after 3 months at which time therapy was changed and that this was regarded as 'remission'. Response of only 3 months is poor and we regard 6 months as the usual criteria for useful response as' outlined in the British Breast Group (1974) Dr Plowman replies:
Sir -I am pleased to answer Robertson and Blamey's comments. I confirm that patient 2 was 3 years postmenopausal, had raised gonadotrophin levels and that both serum oestradiol and serum oestrone levels were in postmenopausal range prior to treatment and that the sex steroids were not influenced by that treatment. I confirm that the nature of the bone metastatic disease in patient 1 was reported (and documented in the published manuscript) as typical of metastatic disease on both plain X-ray and CT scanning of the vertebrae and that (as is clearly shown in Figure 1 of the manuscript) this reverted to normal on the bone scan by day 89 of treatment. I confirm (as clearly stated) that ethical committee approval for the drug ceased at 3 months and that this was the the reason for the alteration in drug therapy at this time; the figure included a day 496 scan to demonstrate the classical behaviour of breast cancer, when relapsing after endocrine therapy, to progress at previous sites of disease -so well known to physicians. I confirm that the sequel to a good response is a remission. The various ramifications of these observations are discussed in the manuscript. 
